Effects of the dual peroxisome proliferator-activated receptor activator aleglitazar in patients with Type 2 Diabetes mellitus or prediabetes.
Erdmann, Erland MD a,*; Califf, Robert MD b; Gerstein, Hertzel C. MD c; Malmberg, Klas MD d,e; Ruilope, Luis MD f; Schwartz, Gregory G. MD g; Wedel, Hans MD h; Volz, Dietmar MD e; Ditmarsch, Marc MD i; Svensson, Anders MD e; Bengus, Monica MD e
[Article]
American Heart Journal.
170(1):117-122, July 2015.
(Format: HTML, PDF)
Background: Insulin-resistant states, including type 2 diabetes (T2D) and prediabetes, are associated with elevated cardiovascular (CV) risk. Aleglitazar is a dual peroxisome proliferator-activated receptor [alpha]/[gamma] agonist with favorable insulin-sensitizing and glucose-lowering actions, favorable effects on blood lipids, and an acceptable safety profile in short-time studies. Therefore, it was hypothesized that aleglitazar would reduce CV morbidity and mortality in patients with T2D mellitus and prediabetes (defined as glycosylated hemoglobin >=5.7% to <6.5%) with previous CV complications.
Study design: ALEPREVENT was a phase III, multicenter, randomized, double-blind, trial comparing aleglitazar 150 [mu]g or placebo daily in patients with T2D or prediabetes with established, stable CV disease. The intended sample size was 19,000 with a primary efficacy measure of major adverse CV events. However, the trial was halted prematurely after 1,999 patients had been randomized because of futility and an unfavorable benefit risk ratio in another CV outcomes trial evaluating aleglitazar.
Results: At study termination after 58 /- 38 days of treatment, data had been collected from 1,996 patients (1,581 with T2D and 415 with pre-T2D). Despite the brief duration of treatment, aleglitazar induced favorable changes in glycosylated hemoglobin and blood lipids, similar for participants with T2D or prediabetes. However, compared with placebo, aleglitazar increased the incidence of hypoglycemia (86 vs 166; P < .0001), and muscular events (3 vs12; P = .012).
Conclusions: Even within a short duration of exposure, aleglitazar was associated with excess adverse events, corroborating the findings of a larger and longer trial in T2D. Coupled with the previous failure of several other peroxisome proliferator-activated receptor [alpha]/[gamma] activators, this class now holds little promise for CV therapeutics.
(C) 2015Elsevier, Inc.
